000 03145nam a22003855i 4500
001 286579
003 MX-SnUAN
005 20160429154507.0
007 cr nn 008mamaa
008 150903s2012 xxu| o |||| 0|eng d
020 _a9781461401407
_99781461401407
024 7 _a10.1007/9781461401407
_2doi
035 _avtls000340200
039 9 _a201509030843
_bVLOAD
_c201404300412
_dVLOAD
_y201402061019
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC261-271
100 1 _aHarrington, David.
_eeditor.
_988498
245 1 0 _aDesigns for Clinical Trials :
_bPerspectives on Current Issues /
_cedited by David Harrington.
250 _a1.
264 1 _aNew York, NY :
_bSpringer New York,
_c2012.
300 _axiv, 206 páginas
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aApplied Bioinformatics and Biostatistics in Cancer Research
500 _aSpringer eBooks
505 0 _aNew designs for phase I dose finding studies -- Phase II/III designs for trials -- Design issues for clinical studies with genomic measurements -- Designing studies with longitudinal measurements subject to dropout -- Issues in sample size re-estimation -- Adaptive designs -- The design of non-inferiority trials -- Issues in the design of HIV prevention trials -- Randomization algorithms -- Sequential designs for phase III studies -- Case studies of difficult designs -- Ethical issues in the design of trials -- Index.
520 _aStatistical methods for clinical trials have been an area of active research in Biostatistics since the first modern clinical trials were mounted in 1946 by the British Medical Research Council in whooping cough and tuberculosis.  Often, the participants in clinical trials suffer from potentially fatal chronic diseases, and it is especially important that these experiments in medical research use designs that are efficient, can be understood by physicians, policy makers and patients, respond quickly new ideas in medicine and statistics, and, perhaps above all, show respect for the complex and important ethical issues that arise in these settings.   This book explores some recent thinking in designs for clinical trials, including alternative designs for phase I studies, interim monitoring for futility, adaptive designs based on accumulating outcome data, and designs of new, targeted therapies.  The book is intended for both the statistical practitioner, who may be too busy to stay abreast of the literature on statistical methods, as well as statisticians conducting research in clinical trials.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781461401391
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4614-0140-7
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c286579
_d286579